Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
11 déc. 2019 08h30 HE
|
Avenue Therapeutics
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
04 nov. 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
28 oct. 2019 08h30 HE
|
Avenue Therapeutics
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced...
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting
18 oct. 2019 08h30 HE
|
Avenue Therapeutics
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
14 août 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
01 août 2019 08h00 HE
|
Avenue Therapeutics
NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
03 juin 2019 07h00 HE
|
Avenue Therapeutics
NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
13 mai 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, May 13, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
30 avr. 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous...
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
12 mars 2019 07h30 HE
|
Avenue Therapeutics
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today...